Zhou Yun, Chen Ping, Huang Qidan, Wan Ting, Jiang Yinan, Jiang Senwei, Yan Sumei, Zheng Min
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
Department of Gynecology, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
Histol Histopathol. 2020 Jul;35(7):721-728. doi: 10.14670/HH-18-203. Epub 2020 Jan 23.
The prognostic application of YES1 in epithelial ovarian cancer (EOC) is currently unclear. We aimed to investigate the expression of YES1 and its correlation with survival outcome in patients with EOC.
A retrospective study of patients diagnosed with EOC at the Cancer Center, Sun Yat-Sen University, Guangzhou, China between 2002 and 2013 was conducted. The immunohistochemical expression of YES1 was assessed using tissue microarray. Survival rates were analyzed by the Kaplan-Meier method and were compared between groups using the log-rank test. Multivariate analyses were performed using the Cox proportional hazards model.
A total of 132 patients with EOC were enrolled. Patients in the YES1-high group exhibited significantly better OS and PFS, compared with those in the YES1-low group (P=0.02 and P=0.03, respectively). Further univariate and multivariate regression analyses indicated YES1 as an independent prognostic factor for the OS of patients with EOC. Notably, within the high YES1 expression group, 40 cases (74.1%) were of the platinum-sensitive group while 14 (25.9%) overlapped were of the platinum-resistant group. Conversely, in the low YES1 expression group, 11 cases (47.8%) were platinum-sensitive, and 12 (52.2%) platinum-resistant. Overall, patients within the high YES1 expression group were deemed significantly more sensitive to platinum-based chemotherapy than the low YES1 expression group (P=0.03), and YES1 levels were consistently and significantly higher in the platinum-sensitive group.
High YES1 cytoplasmic expression in EOC patient tissue is significantly correlated with favorable prognosis. Patients with high YES1 expression tend to be sensitive to platinum-based chemotherapy.
目前尚不清楚YES1在上皮性卵巢癌（EOC）中的预后应用情况。我们旨在研究EOC患者中YES1的表达及其与生存结局的相关性。
对2002年至2013年间在中国广州中山大学肿瘤防治中心诊断为EOC的患者进行回顾性研究。使用组织芯片评估YES1的免疫组化表达。采用Kaplan-Meier法分析生存率，并使用对数秩检验进行组间比较。使用Cox比例风险模型进行多变量分析。
共纳入132例EOC患者。与YES1低表达组相比，YES1高表达组患者的总生存期（OS）和无进展生存期（PFS）显著更好（分别为P=0.02和P=0.03）。进一步的单变量和多变量回归分析表明，YES1是EOC患者OS的独立预后因素。值得注意的是，在YES1高表达组中，40例（74.1%）为铂敏感组，14例（25.9%）为铂耐药组。相反，在YES1低表达组中，11例（47.8%）为铂敏感，12例（52.2%）为铂耐药。总体而言，YES1高表达组患者被认为对铂类化疗的敏感性明显高于YES1低表达组（P=0.03），且铂敏感组的YES1水平始终显著更高。
EOC患者组织中YES1高细胞质表达与良好预后显著相关。YES1高表达的患者往往对铂类化疗敏感。
